Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

22.57 -0.23 (-1.03%)
Streaming Delayed Price Updated: 10:36 AM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about NewAmsterdam Pharma Company N.V. - Ordinary Shares

< Previous 1 2 3 Next >
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears ↗
NewAmsterdam Pharma (NASDAQ:NAMS) used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial... 
Via MarketBeat
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. 
Via The Motley Fool
NewAmsterdam Pharma (NASDAQ:NAMS) Beats Q1 Revenue and EPS Estimates as Key Trial Catalysts Loom ↗
Via Chartmill
News headline image
7 Analysts Have This To Say About NewAmsterdam Pharma ↗
 
Via Benzinga
News headline image
Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) ↗
 
Via Benzinga
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. 
Via The Motley Fool
News headline image
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends ↗
NewAmsterdam Pharma (NASDAQ:NAMS) said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what... 
Via MarketBeat
News headline image
This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials. 
Via The Motley Fool
News headline image
Where NewAmsterdam Pharma Stands With Analysts ↗
 
Via Benzinga
News headline image
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Gets Booted in Latest Fund Update ↗
Bain Capital sold its entire stake in Nuvalent stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗
Bain Capital completely exited its position in Disc Medicine stock during the third quarter 
Via The Motley Fool
News headline image
Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts ↗
 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co ↗
 
Via Benzinga
News headline image
NewAmsterdam (NAMS) Q2 Revenue Jumps 49% ↗
Via The Motley Fool
News headline image
What Analysts Are Saying About NewAmsterdam Pharma Co Stock ↗
 
Via Benzinga
News headline image
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib ↗
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation. 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Monday's pre-market session. ↗
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts ↗
 
Via Benzinga
News headline image
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily
News headline image
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? ↗
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.